FINHUB Insights

WST · Q1 FY26 · Jan 1 – Mar 31, 2026

West Pharmaceutical Services Q1 FY26: where the revenue came from and where it went

West Pharmaceutical Services Q1 FY26: revenue $0.8B (+21% year over year). Net profit $0.1B. Largest cohort Proprietary Products $0.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2026
Reported
Apr 23, 2026 10-Q
Sankey diagram of West Pharmaceutical Services's income statement for Q1 FY26: revenue of $0.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.8B +21% year over year
Gross profit$0.3B 35% margin
Operating profit$0.2B 21% margin
Net profit$0.1B 16% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 0.8 100% +21%
Proprietary Products 0.7 88% +23%
West Vantage Segment 0.2 25% +12%
Cost of revenue−0.562%
Gross profit0.335% margin+2pp
Research & development−02%+0pp
SG&A−0.112%−1pp
Other−00%+0pp
Operating profit0.221% margin+6pp
Net profit0.116%+4pp
Filing on EDGAR More quarters of WST

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters